ALZFORUM2d
Donanemab Clinical Use Growing in U.S., Rejected in Europe
Like lecanemab before it, donanemab’s path to market has been slow and rocky. In the U.S., the antibody received Food and ...
XFOR: Full Enrollment of Phase 3 4WARD Trial Expected in 2H25…
XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Full Enrollment of Phase 3 4WARD Trial Expected in 2H25 X4 ...
Frontiers3d
Traditional Clinical Symptoms and Signs: How Can They Be Used to Investigate Medications in the Context of Pharmacology?
Clinical symptoms and signs are a bridge between biomedicine and traditional medicine [TM]. These can be associated with diseases incl. their diagnosis, pharmacological targets, and the use of ...
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results
On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of ...
MedPage Today5d
Routine Urodynamics Fails to Improve Overactive Bladder Beyond Clinical Evaluation
Routine use of urodynamic testing for overactive bladder (OAB) did not improve patient-reported outcomes when combined with ...
Avant Technologies and Ainnova Begin Designing Clinical Trial Protocol for Company’s Vision AI Platform
Avant Technologies Inc. (OTCQB:AVAI) (”Avant” or the “Company”), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease ...
Clinical Trials Arena5d
FDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatment
Imunon has announced the alignment of the FDA with the Phase III OVATION 3 trial of IMNN-001 for ovarian cancer protocol.
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March ...
The Manila Times6d
IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Company to hold conference call on Tuesday, March 25, 2025, at 2:00 ...